From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.31
First Reported 2003
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 7
Disease Relevance 2.68
Pain Relevance 0.63

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Golgi apparatus (Ctla4) plasma membrane (Ctla4)
Anatomy Link Frequency
T cell 2
CD86 1
dendritic cells 1
Ctla4 (Mus musculus)
Pain Link Frequency Relevance Heat
abatacept 10 98.12 Very High Very High Very High
rheumatoid arthritis 62 92.88 High High
Inflammation 45 78.40 Quite High
cytokine 84 75.64 Quite High
tolerance 9 65.00 Quite High
chemokine 24 50.00 Quite Low
antagonist 3 17.12 Low Low
Crohn's disease 3 14.76 Low Low
Multiple sclerosis 3 12.36 Low Low
Arthritis 8 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Immunotherapy Of Cancer 11 98.86 Very High Very High Very High
Cancer 293 97.96 Very High Very High Very High
Rheumatoid Arthritis 62 92.88 High High
Glioma 11 91.60 High High
Inflammatory Bowel Disease 3 90.60 High High
Disease 24 88.72 High High
Diabetes Mellitus 12 85.92 High High
Obesity 3 85.36 High High
Autoimmune Disease 28 78.56 Quite High
INFLAMMATION 48 78.40 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
CTLA-4 blocking with a specific antibody, but not IL-10 blocking, abrogated the activity of CD4(+) CD25(+) cells.
Negative_regulation (blocking) of CTLA-4
1) Confidence 0.31 Published 2009 Journal J. Dermatol. Sci. Section Body Doc Link 19157794 Disease Relevance 0.07 Pain Relevance 0
We here demonstrate that CD28 signalling suppresses Th17 differentiation, while CTLA4-Ig blockade promotes mouse and human Th17 polarization in vitro.

Negative_regulation (blockade) of CTLA4
2) Confidence 0.27 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2658739 Disease Relevance 0.82 Pain Relevance 0.14
We here demonstrate in vitro that ligation of CD28 with a monoclonal antibody results in inhibition of Th17 differentiation whereas CTLA4-Ig blockade enhances it during APC/T cell interactions.
Negative_regulation (blockade) of CTLA4 in T cell
3) Confidence 0.27 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2658739 Disease Relevance 0.07 Pain Relevance 0.04
It remains to be investigated, however, whether CTLA4 depletion might also interfere with the clonal expansion of tumor-antigen specific T lymphocytes.
Negative_regulation (depletion) of CTLA4 in T lymphocytes associated with cancer
4) Confidence 0.26 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2291560 Disease Relevance 0.48 Pain Relevance 0.03
Abatacept (CTLA4-Ig) can mimic one of the endogenous regulatory pathways by reproducing the inhibitory effect of CTLA4.
Negative_regulation (effect) of CTLA4 associated with abatacept
5) Confidence 0.17 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2582809 Disease Relevance 0.32 Pain Relevance 0.42
The opposite is desirable in cancer treatment and the co-stimulatory pathway can be activated through blockade of CTLA4 and/or transfer of CD80/CD86 [85, 86].
Negative_regulation (blockade) of CTLA4 in CD86 associated with immunotherapy of cancer
6) Confidence 0.17 Published 2003 Journal J Biomed Biotechnol Section Body Doc Link PMC179760 Disease Relevance 0.79 Pain Relevance 0
In APC/T cell co-cultures, mature dendritic cells (DC) were less efficient than immature DC in their ability to support Th17 cell differentiation, while CTLA4-Ig, an agent blocking CD28/B7 and CTLA4/B7 interactions, facilitated both murine and human Th17 differentiation.
Negative_regulation (blocking) of CTLA4 in dendritic cells
7) Confidence 0.12 Published 2009 Journal PLoS ONE Section Abstract Doc Link PMC2658739 Disease Relevance 0.14 Pain Relevance 0

General Comments

This test has worked.

Personal tools